产品
编 号：F702473
分子式：C338H516N88O108S4
分子量：7668.48
分子式：C338H516N88O108S4
分子量：7668.48
产品类型
规格
价格
是否有货
结构图
CAS No: 166089-33-4
产品详情
生物活性：
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis.
体内研究：
Nagrestipen (ECI 301) (i.v; 2 μg; daily for 5 days) significantly inhibits tumor growth at 6 Gy local irradiation of tumor sites and enhances the distant septal effect of radiation in male BALB/c mice.Nagrestipen (ECI 301) (i.v; 0.08, 0.4, 2 μg; day 1,8,15) can inhibit tumor growth in a dose-dependent manner at both irradiated and unirradiated sites of female C57BL/6 with LLC cells.Animal Model:Male BALB/c mice with Colon26 cells and MethA cells
Dosage:2 μg
Administration:Intravenous injection; daily for 5 days
Result:Significantly inhibited tumor size without significant toxicity.Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated.
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis.
体内研究：
Nagrestipen (ECI 301) (i.v; 2 μg; daily for 5 days) significantly inhibits tumor growth at 6 Gy local irradiation of tumor sites and enhances the distant septal effect of radiation in male BALB/c mice.Nagrestipen (ECI 301) (i.v; 0.08, 0.4, 2 μg; day 1,8,15) can inhibit tumor growth in a dose-dependent manner at both irradiated and unirradiated sites of female C57BL/6 with LLC cells.Animal Model:Male BALB/c mice with Colon26 cells and MethA cells
Dosage:2 μg
Administration:Intravenous injection; daily for 5 days
Result:Significantly inhibited tumor size without significant toxicity.Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备